SCHEMBL27201291

SCHEMBL27201291

CC(C)c1cc(N2C=C(c3ccccc3Br)CCC2)nc(N)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.41
HRH4 Q9H3N8 5/20 0.40
HTR1B P28222 1/20 0.36
HTR2B P41595 1/20 0.36
GPR65 Q8IYL9 1/20 0.36
NUDT1 P36639 1/20 0.33
CDK1 P06493 1/20 0.31
CDK2 P24941 1/20 0.31
ADORA2A P29274 1/20 0.31
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30
HTT P42858 1/20 0.30
HSD17B10 Q99714 1/20 0.30
PTPN1 P18031 1/20 0.30
MAPT P10636 1/20 0.30
GFER P55789 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30834176 1.00 HRH3 (0.41) HRH3HRH4HTR1BHTR2BGPR65
SCHEMBL27201269 0.77 HRH3 (0.45) HRH3HRH4HTR1BHTR2BGPR65
SCHEMBL30834132 0.77 HRH3 (0.45) HRH3HRH4HTR1BHTR2BGPR65
Hydrochloric Acid SCHEMBL7079617 0.68 NUDT1 (0.65) HRH3HRH4NUDT1USP2LMNA
SCHEMBL30834116 0.67 HRH4 (0.52) HRH3HRH4MAPTGFER
SCHEMBL30834210 0.66 HRH3 (0.43) HRH3HRH4HTR1BHTR2BGPR65
SCHEMBL30834252 0.66 HRH3 (0.43) HRH3HRH4HTR1BHTR2BGPR65
SCHEMBL27201588 0.66 HRH3 (0.43) HRH3HRH4HTR1BHTR2BGPR65
SCHEMBL27201459 0.66 HRH3 (0.43) HRH3HRH4HTR1BHTR2BGPR65
SCHEMBL30885293 0.65 HRH4 (0.49) HRH3HRH4USP2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US claimed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO claimed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP HRH3 4300/4885HRH4 4074/4885HTR1B 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.